Hadassah

Hadassah Drug to Fight Fatty Liver Disease Progressing Well in US Clinical Trials

Thursday, Sep 3 2015

Clinical trials with a Hadassah-developed technology to treat fatty liver disease are moving forward in 25 medical centers, in the United States and Australia. Fatty liver disease, in its severe form—called non-alcoholic steatohepatitis (NASH)—can lead to cirrhosis and liver cancer and there are currently no other treatments available.

Among the US test sites are the Cleveland Clinic (Ohio), Duke Liver Center (Durham, NC), Baylor St. Luke's Medical Center (Houston, Tex), and University of Virginia (Charlottesville). The Australian sites include Westmead Hospital (Sydney) and The Alfred (Melbourne).

Hadasit, Hadassah’s technology transfer arm, and Immuron, an Australian biopharmaceutical company, worked together to develop the product, being referred to as IMM-124E. The collaborative effort combines Hadassah’s oral immune modulation approach with antibodies produced by Immuron. See http://www.hadassah.org/news-stories/fda-grants-approval-for-us.html

Immuron has also announced that it is beginning a United States Investor Roadshow, where it will showcase its technology platform and profile to US investment groups. The company reports that its clinical trials “are progressing well” and that “a recent Deutsche Bank review of the NASH market suggests that there is a worldwide market for NASH of between $35-40 billion.” The company further explains that “the high prevalence of Type 2 diabetes and obesity, which leads to NASH and other non-alcoholic fatty liver diseases, boosts the prevalence of NASH and its market growth.”

View the Roadshow presentation: http://www.immuron.com/index.php/download_file/-/view/142/

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, Jan 10 2017

From Locked Jaw to Osteoarthritis: Hadassah Discovery Leads to New Treatment

What began as a solution to locked jaw--temporomandibular joint (TMJ) disorder--has led to the creation of a novel non-opioid pharmaceutical candidate for the treatment of osteoarthritis pain, thanks to a Hadassah Medical Organization discovery and collaboration with colleagues at the Hebrew University and the Technion.

READ MORE ›
alt_text

Monday, Jan 9 2017

Soldiers Rushed to Hadassah After Sunday's Terrorist Attack

On Sunday January 8, four soldiers were killed and 17 wounded, when a terrorist rammed his vehicle into them.

READ MORE ›
alt_text

Monday, Jan 9 2017

Prime Minister Netanyahu visits terror survivors at Hadassah Hospital

Prime Minister Benjamin Netanyahu and Health Minister Yaakov Litzman visited terror victims hospitalized at Hadassah Hospital Ein Kerem after a terrorist rammed his flatbed truck into a group of soldiers on an IDF cultural field trip in Jerusalem. Four were killed, and 11 patients underwent treatment at Hadassah hospitals: 9 at Ein Kerem and 2 at Mount Scopus.

READ MORE ›
alt_text

Friday, Jan 6 2017

World-First Newborn Intestinal Surgery Saves Baby Girl at Hadassah

A baby girl whose intestines formed outside of her abdomen was saved by a world-first surgical procedure following her birth at Hadassah Hospital Ein Kerem.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More